Amp Volatility Score
Catalyst Info & Data Links
TITLE: DUR-928 for Alcoholic Hepatitis (AH) - Phase 2
ClinicalTrials.gov (NCT04563026): A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment (AHFIRM)
WHAT IS THE NEXT CATALYST EVENT?
Dosing First Patients/Readout in the Future
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
TBD (Latest Quarterly Call says anyday)
MECHANISM OF ACTION
DURECT's lead drug candidate, DUR-928, is an endogenous sulfated oxysterol and an epigenetic regulator. It represents a new class of therapeutics with a unique mechanism of action. DUR-928 epigenetically modulates the expression of multiple clusters of master genes that are involved in many important cell signaling pathways, through which it stabilizes mitochondria, reduces lipotoxicity, regulates inflammatory or stress responses, and promotes cell survival.
Updated by JM
DRRX, Durect, Alcoholic Hepatitis (AH), DUR-928
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post